341
A Dutch biotech company has announced, that their recombinant human C1 inhibitor (rhC1INH) dossier for compassionate use filings to treat hereditary angioedema (HAE) is already completed. Applications for orphan drug designation (ODD) for the use of rhC1INH for other indications are also submitted. ODD is granted by (EMEA) to promote the development of products that may offer therapeutic benefits for diseases, affecting less than five in 10,000 people in the European Union (EU).